Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2026-01-28 Capital/Financing Update
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a strategic partnership, the creation of a joint venture in Asia, and the securing of $20 million in financing for a Phase 3 clinical trial. This falls under the category of capital and financing updates as it details the injection of funds and the formation of a new corporate entity for business expansion.
2026-01-28 English
Biophytis participe à la JP Morgan Healthcare Conference et au Biomed Forum
Regulatory Filings Classification · 95% confidence The document is a press release announcing the company's participation in upcoming investor conferences (JP Morgan Healthcare Conference and Biomed Forum). It does not contain financial results, board changes, or specific regulatory filings, but rather serves as a general corporate announcement regarding investor relations activities. As it does not fit into specific categories like earnings releases or reports, it falls under the general regulatory announcement category.
2026-01-12 French
Biophytis to Participate in the JP Morgan Healthcare Conference and the Biomed Forum
Regulatory Filings Classification · 95% confidence The document is a press release announcing the company's participation in upcoming healthcare and investment conferences (JP Morgan Healthcare Conference and Biomed Forum). It does not contain financial statements, voting results, or specific regulatory filings, but rather serves as a general corporate announcement regarding investor relations activities. As it does not fit into specific categories like 'Investor Presentation' (which would be the slides themselves) or 'Earnings Release', it falls under the general regulatory/corporate announcement category.
2026-01-12 English
RESULTS OF THE COMBINED GENERAL MEETING ON NOVEMBER 13, 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement regarding the results of a Combined General Meeting held on November 13, 2025. It explicitly states that all resolutions presented by the company were adopted and provides information on the quorum and the availability of detailed voting results on the company website. This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2025-11-13 English
RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 13 NOVEMBRE 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'RÉSULTATS DE L'ASSEMBLÉE GÉNÉRALE MIXTE' (Results of the Combined General Meeting) and explicitly states that all resolutions proposed by the company were approved. It provides details on the quorum and mentions that the full voting results are available on the company's website. This fits the definition of a Declaration of Voting Results (DVA).
2025-11-13 French
Biophytis Reports First-Half 2025 Results and Provides Strategic Update
Earnings Release Classification · 95% confidence The document is a press release titled 'Biophytis Reports First-Half 2025 Results and Provides Strategic Update'. It provides a summary of financial highlights, cash position, and strategic outlook for the first half of the year. While it contains financial tables, it is structured as a corporate announcement (press release) rather than a full statutory interim report. According to the 'Menu vs Meal' rule, this is an announcement of results, which falls under the Earnings Release (ER) category. H1 2025
2025-10-30 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.